Twist Bioscience Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Twist Bioscience Corporation on May 23, 2023. The report discloses a material change in the Company's executive leadership structure regarding the appointment of a new Chief Accounting Officer.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel changes and compensation arrangements.
Material Changes
- Appointment: The Board of Directors appointed Robert F. Werner as Chief Accounting Officer and Principal Accounting Officer, effective May 22, 2023.
- Role Transition: James Thorburn, the Chief Financial Officer, previously served as Principal Accounting Officer and will continue as CFO and Principal Financial Officer.
- Compensation Package for Mr. Werner:
- Annual base salary: $400,000
- Fiscal year 2023 bonus: $100,000
- Equity grant: 30,000 restricted stock units (vesting over four years with a one-year cliff)
Outlook, Risks, and Management Commentary
The filing contains no guidance, outlook, or discussion of risks and contingencies. It notes that Mr. Werner has no family relationships with directors or officers and no material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Robert F. Werner's appointment (May 22, 2023).
- Confirm the specific vesting schedule of the 30,000 restricted stock units granted.
- Review the attached press release (Exhibit 99.1) for additional context on the leadership transition.
- Note that this filing does not contain updated financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.